Dasiglucagon in severe hypoglycemia: a profile of its use

Authors: Yahiya Y. Syed

Abstract 

Subcutaneous dasiglucagon (Zegalogue®), a next generation glucagon analog, is a convenient and valuable addition to ready-to-use glucagon formulations for the rescue treatment of severe hypoglycemia in patients aged ≥ 6 years with diabetes. A single dose of dasiglucagon reverses insulin-induced hypoglycemia typically within 10 min in this population, without need for additional intervention. The drug is generally well tolerated, with nausea and vomiting being the most frequent adverse reactions. The overall safety profile of dasiglucagon is consistent with that expected for glucagon treatment. Dasiglucagon is available in convenient auto-injector and prefilled syringe forms that can be carried at room temperature.

Plain Language Summary

Glucagon emergency kits are a standard treatment option for hypoglycemia, a potential serious complication of diabetes treatment. They require mixing of glucagon powder in sterile water before administration; this step may cause errors and delay in an emergency situation. Thus, ready-to-use glucagon formulations have been developed. Subcutaneous dasiglucagon (Zegalogue®), a ready-to-use next generation glucagon analog, is approved in the USA for the rescue treatment of severe hypoglycemia in patients aged ≥ 6 years with diabetes. Dasiglucagon reverses hypoglycemia typically within 10 min, without need for additional intervention, and is well tolerated. The drug is available in convenient auto-injector and prefilled syringe forms that can be carried at room temperature. Thus, dasiglucagon is a convenient and valuable addition to ready-to-use glucagon formulations for the treatment of severe hypoglycemia.